Ulipristal Acetate
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
126784-99-4CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21COOLLAFOLCSJHRE-ZHAKMVSLSA-NUlipristal acetate is a 20-oxo steroid obtained by acetylation of the 17-hydroxy group of (11beta,17alpha)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-ol (ulipristal). A selective progesterone receptor modulator, which is employed as an emergency contraceptive. It has a role as a contraceptive drug, a progestin and a progesterone receptor modulator. It is a 20-oxo steroid, an acetate ester, a steroid ester, a 3-oxo-Delta(4) steroid and a tertiary amino compound. It is functionally related to an estradiol.
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
化学的特性Pale Yellow Solid
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Danger
H302 (75%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P261, P263, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 8 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Ulipristal acetate
vLess-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
ULIPRISTAL ACETATE
Selective Progesterone Receptor Modulators [MoA]; Progesterone Agonist/Antagonist [EPC]
Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading.
Contraceptive agents that act on the ENDOCRINE SYSTEM.
説明Ulipristal acetate is a synthetic steroid derived from 19-nor-progesterone that exerts potent progesterone receptor (PR) antagonist activity at the transcriptional level. It is an orally administered drug indicated for emergency contraception (i.e., postcoital contraception) up to 120 h following unprotected intercourse. Ulipristal acetate is the second oral progestogen marketed for this indication behind levonorgestrel. As PR antagonists, both drugs are believed to act via delay of ovulation and inhibition of follicular development. Levonorgestrel 1.5 mg is approved for contraception up to 72 h following unprotected intercourse and is widely accessible via prescription, and directly from clinics and community pharmacies. Prior to ulipristal acetate, the only approved postcoital contraceptive option between 72 and 120 h was the insertion of an intrauterine device (IUD). The recommended dose of ulipristal acetate is one 30-mg tablet taken as soon as possible and no more than 120 h following intercourse. The vast majority of PR antagonists belonging to the mifepristone (RU486) family also bind to the glucocorticoid receptor (GR) with high affinity and thereby exert antiglucocorticoid activity. The most common adverse effects with ulipristal acetate were headache, dysmenorrhea, nausea, abdominal pain, dizziness, fatigue, and upper abdominal pain.
使用Ulipristal acetate is a selective progesterone receptor modulator
ChEBI: A 20-oxo steroid obtained by acetylation of the 17-hydroxy group of (11beta,17alpha)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-ol (ulipristal). A selective progesterone receptor modulator, which is empl yed as an emergency contraceptive.
126784-99-4DTXSID30155294CHEMBL260538CHEBI:71025